news

— DUR-928 is an inhibitor of DNA methyltransferases (DNMTs) regulating expression of genes involved in cell survival, inflammation and lipid biosynthesis — Mechanism of action supports development of DUR-928 for the treatment of multiple acute organ injury and chronic diseases — Published in peer reviewed Journal of Lipid Research CUPERTINO, Calif., March 9, 2021 /PRNewswire/ […]

Webcast of Earnings Call Today, March 4th at 4:30 p.m. Eastern Time CUPERTINO, Calif., March 4, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2020 and provided a corporate update.   “We have achieved a number of important milestones over the past few months,

CUPERTINO, Calif., March 3, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in three upcoming investor conferences, taking place in March 2021.  All conferences will take place virtually. Details are as follow: H.C. Wainwright Life Sciences Conference: March 9 – 10 Presentation Date: March 9  Time: Available on demand from 7:00 am

CUPERTINO, Calif., Feb. 25, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and year ended December 31, 2020 financial results and host a conference call after the market close on Thursday, March 4, 2021. Thursday, March 4 @ 4:30pm Eastern Time / 1:30 p.m. Pacific Time Toll Free: 877-407-0784 International: 

CUPERTINO, Calif., Feb. 4, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT“), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced the pricing of its underwritten public offering of 17,708,333 shares of its

CUPERTINO, Calif., Feb. 3, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) (“DURECT“), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program, today announced that it is commencing an underwritten public offering of its common stock

POSIMIR is the only approved sustained-release bupivacaine product indicated for up to 72 hours of post-surgical analgesia from a single application Conference Call Today, February 2, 2021 at 4:30pm ET CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution)

CUPERTINO, Calif., Jan. 25, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase 2b study to evaluate the safety and efficacy of DUR-928 in severe alcohol-associated hepatitis (AH) patients. “We are excited to have begun dosing severe AH patients in the AHFIRM

CUPERTINO, Calif., Jan. 5, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience. “We are pleased to welcome Ms. Maderis

CUPERTINO, Calif., Jan. 4, 2021 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that the sale of the LACTEL product line to Evonik closed and the $15 million payment was received on December 31, 2020. About DURECT CorporationDURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and